Bee Venom Phospholipase A2, a Good "Chauffeur" for Delivering Tumor Antigen to the MHC I and MHC II Peptide-Loading Compartments of the Dendritic Cells: The Case of NY-ESO-1

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Almunia, Christine ^a,c   Bretaudeau, Marie ^c   Held, Gerhard ^b   Babon, Aurélie ^a   Marchetti, Charles ^c   Castelli, Florence Anne ^a   Ménez, André ^a,d   Maillere, Bernard ^a   Gillet, Daniel ^a  

^a Institute Frederic Joliot   (France)

^b Medizinische Klinik I   (Germany)

^c DIF   (France)

^d MUSÉUM NATIONAL D'HISTOIRE NATURELLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BEE VENOM PHOSPHOLIPASE A2; DENDRITIC CELL VACCINE; HLA ANTIGEN CLASS 2; HYBRID PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NY ESO 1 ANTIGEN; PEPTIDE; PHOSPHOLIPASE A2; PROTEIN PNY; UNCLASSIFIED DRUG; BEE VENOM; TUMOR ANTIGEN;

ANTIGEN BINDING; ARTICLE; CANCER CELL CULTURE; CARBOXY TERMINAL SEQUENCE; CD8+ T LYMPHOCYTE; CELL COMPARTMENTALIZATION; CELL MEMBRANE; CROSS PRESENTATION; DENDRITIC CELL; IMMUNOGENICITY; LYMPHOCYTE ACTIVATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA CELL; MEMBRANE BINDING; MOLECULAR RECOGNITION; MONOCYTE; PROTEIN BINDING; PROTEIN STRUCTURE; TH1 CELL; VACCINE PRODUCTION; ENZYMOLOGY; HUMAN; IMMUNOLOGY; METABOLISM;

APOIDEA;

ANTIGENS, NEOPLASM; BEE VENOMS; DENDRITIC CELLS; HUMANS; MAJOR HISTOCOMPATIBILITY COMPLEX; PHOSPHOLIPASES A2;

EID: 84879153343     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0067645     Document Type: Article

References (44)

1. Banchereau J, Palucka AK, (2005) Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 5: 296-306. doi:10.1038/nri1592. PubMed: 15803149.
2. Villunger A, Strasser A, (1999) The great escape: is immune evasion required for tumor progression? Nat Med 5: 874-875. doi:10.1038/11311. PubMed: 10426306.
3. De Luca A, Iannitti RG, Bozza S, Beau R, Casagrande A, et al. (2012) CD4(+) T cell vaccination overcomes defective cross-presentation of fungal antigens in a mouse model of chronic granulomatous disease. J Clin Invest 122: 1816-1831. doi:10.1172/JCI60862. PubMed: 22523066.
4. Palucka AK, Ueno H, Fay J, Banchereau J, (2008) Dendritic cells: a critical player in cancer therapy? J Immunother 31: 793-805. doi:10.1097/CJI.0b013e31818403bc. PubMed: 18833008.
5. Gilboa E, (2007) DC-based cancer vaccines. J Clin Invest 117: 1195-1203. doi:10.1172/JCI31205. PubMed: 17476349.
6. den Brok MH, Nierkens S, Figdor CG, Ruers TJ, Adema GJ, (2005) Dendritic cells: tools and targets for antitumor vaccination. Expert Rev Vaccines 4: 699-710. doi:10.1586/14760584.4.5.699. PubMed: 16221071.
7. Yewdell JW, Schubert U, Bennink JR, (2001) At the crossroads of cell biology and immunology: DRiPs and other sources of peptide ligands for MHC class I molecules. J Cell Sci 114: 845-851. PubMed: 11181168.
8. Ackerman AL, Cresswell P, (2004) Cellular mechanisms governing cross-presentation of exogenous antigens. Nat Immunol 5: 678-684. doi:10.1038/nrm1474. PubMed: 15224093.
9. Guermonprez P, Amigorena S, (2005) Pathways for antigen cross presentation. Springer Semin Immunopathol 26: 257-271. doi:10.1007/s00281-004-0176-0. PubMed: 15592842.
10. Beinart G, Rini BI, Weinberg V, Small EJ, (2005) Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer. Clin Prostate Cancer 4: 55-60. doi:10.3816/CGC.2005.n.013. PubMed: 15992463.
11. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, et al. (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363: 411-422. doi:10.1056/NEJMoa1001294. PubMed: 20818862.
12. Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, et al. (2009) Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115: 3670-3679. doi:10.1002/cncr.24429. PubMed: 19536890.
13. Zarei S, Schwenter F, Luy P, Aurrand-Lions M, Morel P, et al. (2009) Role of GM-CSF signaling in cell-based tumor immunization. Blood 113: 6658-6668. doi:10.1182/blood-2008-06-161075. PubMed: 19282460.
14. Jain MK, Yu BZ, Rogers J, Ranadive GN, Berg OG, (1991) Interfacial catalysis by phospholipase A2: dissociation constants for calcium, substrate, products, and competitive inhibitors. Biochemistry 30: 7306-7317. doi:10.1021/bi00243a036. PubMed: 1854739.
15. Annand RR, Kontoyianni M, Penzotti JE, Dudler T, Lybrand TP, et al. (1996) Active site of bee venom phospholipase A2: the role of histidine-34, aspartate-64 and tyrosine-87. Biochemistry 35: 4591-4601. doi:10.1021/bi9528412. PubMed: 8605210.
16. Babon A, Almunia C, Boccaccio C, Beaumelle B, Gelb MH, et al. (2005) Cross-presentation of a CMV pp65 epitope by human dendritic cells using bee venom PLA2 as a membrane-binding vector. FEBS Lett 579: 1658-1664. doi:10.1016/j.febslet.2005.02.019. PubMed: 15757657.
17. Chen YT, Scanlan MJ, Sahin U, Türeci O, Gure AO, et al. (1997) A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A 94: 1914-1918. doi:10.1073/pnas.94.5.1914. PubMed: 9050879.
18. Chen YT, Boyer AD, Viars CS, Tsang S, Old LJ, et al. (1997) Genomic cloning and localization of CTAG, a gene encoding an autoimmunogenic cancer-testis antigen NY-ESO-1, to human chromosome Xq28. Cytogenet Cell Genet 79: 237-240. doi:10.1159/000134734. PubMed: 9605863.
19. Jäger E, Chen YT, Drijfhout JW, Karbach J, Ringhoffer M, et al. (1998) Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 187: 265-270. doi:10.1084/jem.187.2.265. PubMed: 9432985.
20. Jäger E, Stockert E, Zidianakis Z, Chen YT, Karbach J, et al. (1999) Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correlation with clinical events. Int J Cancer 84: 506-510. doi:10.1002/(SICI)1097-0215(19991022)84:5. PubMed: 10502728.
21. Gnjatic S, Nishikawa H, Jungbluth AA, Güre AO, Ritter G, et al. (2006) NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res 95: 1-30. doi:10.1016/S0065-230X(06)95001-5. PubMed: 16860654.
22. Zeng G, Aldridge ME, Tian X, Seiler D, Zhang X, et al. (2006) Dendritic cell surface calreticulin is a receptor for NY-ESO-1: direct interactions between tumor-associated antigen and the innate immune system. J Immunol 177: 3582-3589. PubMed: 16951317.
23. Held G, Matsuo M, Epel M, Gnjatic S, Ritter G, et al. (2004) Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments. Eur J Immunol 34: 2919-2929. doi:10.1002/eji.200425297. PubMed: 15368308.
24. Raussens V, Ruysschaert JM, Goormaghtigh E, (2003) Protein concentration is not an absolute prerequisite for the determination of secondary structure from circular dichroism spectra: a new scaling method. Anal Biochem 319: 114-121. doi:10.1016/S0003-2697(03)00285-9. PubMed: 12842114.
25. Scott DL, Otwinowski Z, Gelb MH, Sigler PB, (1990) Crystal structure of bee-venom phospholipase A2 in a complex with a transition-state analogue. Science 250: 1563-1566. doi:10.1126/science.2274788. PubMed: 2274788.
26. Harding C, Heuser J, Stahl P, (1983) Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. J Cell Biol 97: 329-339. doi:10.1083/jcb.97.2.329. PubMed: 6309857.
27. Bolte S, Cordelières FP, (2006) A guided tour into subcellular colocalization analysis in light microscopy. J Microsc 224: 213-232. doi:10.1111/j.1365-2818.2006.01706.x. PubMed: 17210054.
28. Li Q, Lau A, Morris TJ, Guo L, Fordyce CB, et al. (2004) A syntaxin 1, Galpha(o), and N-type calcium channel complex at a presynaptic nerve terminal: analysis by quantitative immunocolocalization. J Neurosci 24: 4070-4081. doi:10.1523/JNEUROSCI.0346-04.2004. PubMed: 15102922.
29. Illinger D, Poindron P, Kuhry JG, (1991) Fluid phase endocytosis investigated by fluorescence with trimethylamino-diphenylhexatriene in L929 cells; the influence of temperature and of cytoskeleton depolymerizing drugs. Biol Cell 73: 131-138. doi:10.1016/0248-4900(91)90095-5. PubMed: 1804505.
30. Mandic M, Castelli F, Janjic B, Almunia C, Andrade P, et al. (2005) One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma. J Immunol 174: 1751-1759. PubMed: 15661941.
31. Rock KL, Rothstein L, Gamble S, Fleischacker C, (1993) Characterization of antigen-presenting cells that present exogenous antigens in association with class I MHC molecules. J Immunol 150: 438-446. PubMed: 8419476.
32. Maillère B, Mourier G, Hervé M, Cotton J, Leroy S, et al. (1995) Immunogenicity of a disulphide-containing neurotoxin: presentation to T-cells requires a reduction step. Toxicon 33: 475-482. doi:10.1016/0041-0101(94)00186-C. PubMed: 7570632.
33. Guil S, Rodríguez-Castro M, Aguilar F, Villasevil EM, Antón LC, et al. (2006) Need for tripeptidyl-peptidase II in major histocompatibility complex class I viral antigen processing when proteasomes are detrimental. J Biol Chem 281: 39925-39934. doi:10.1074/jbc.M608522200. PubMed: 17088258.
34. Luckey CJ, King GM, Marto JA, Venketeswaran S, Maier BF, et al. (1998) Proteasomes can either generate or destroy MHC class I epitopes: evidence for nonproteasomal epitope generation in the cytosol. J Immunol 161: 112-121. PubMed: 9647214.
35. Shen H, Ackerman AL, Cody V, Giodini A, Hinson ER, et al. (2006) Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology 117: 78-88. doi:10.1111/j.1365-2567.2005.02268.x. PubMed: 16423043.
36. Mason D, (1998) A very high level of crossreactivity is an essential feature of the T-cell receptor. Immunol Today 19: 395-404. doi:10.1016/S0167-5699(98)01299-7. PubMed: 9745202.
37. Bioley G, Guillaume P, Luescher I, Bhardwaj N, Mears G, et al. (2009) Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-expressing Tumors. J Immunother 32: 161-168. doi:10.1097/CJI.0b013e31819302f6. PubMed: 19238015.
38. Kreer C, Rauen J, Zehner M,. (2011) Burgdorf S Cross-presentation: how to get there- or how to get the ER. Front Immunol 2: 87. PubMed: 22566876.
39. Carey TE, Takahashi T, Resnick LA, Oettgen HF, Old LJ, (1976) Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells. Proc Natl Acad Sci U S A 73: 3278-3282. doi:10.1073/pnas.73.9.3278. PubMed: 1067619.
40. Odunsi K, Qian F, Matsuzaki J, Mhawech-Fauceglia P, Andrews C, et al. (2007) Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci U S A 104: 12837-12842. doi:10.1073/pnas.0703342104. PubMed: 17652518.
41. Zarour HM, Kirkwood JM, Kierstead LS, Herr W, Brusic V, et al. (2000) Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells. Proc Natl Acad Sci U S A 97: 400-405. doi:10.1073/pnas.97.1.400. PubMed: 10618430.
42. Buhot C, Chenal A, Sanson A, Pouvelle-Moratille S, Gelb MH, et al. (2004) Alteration of the tertiary structure of the major bee venom allergen Api m 1 by multiple mutations is concomitant with low IgE reactivity. Protein Sci 13: 2970-2978. PubMed: 15459335.
43. Chenal A, Savarin P, Nizard P, Guillain F, Gillet D, et al. (2002) Membrane protein insertion regulated by bringing electrostatic and hydrophobic interactions into play. A case study with the translocation domain of diphtheria toxin. J Biol Chem 277: 43425-43432. doi:10.1074/jbc.M204148200. PubMed: 12193591.
44. Tavallaie M, Chenal A, Gillet D, Pereira Y, Manich M, et al. (2004) Interaction between the two subdomains of the C-terminal part of the botulinum neurotoxin A is essential for the generation of protective antibodies. FEBS Lett 572: 299-306. doi:10.1016/j.febslet.2004.06.094. PubMed: 15304366.